HPTN 083 is a research study that compares the effectiveness of injections
and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV.
HPTN 083 is a study that is part of the NIH-DAIDS-funded HIV Prevention Trials Network (HPTN). Learn more under Additional Information.
CABOTEGRAVIR FOR PREP
HPTN 083 is the first large-scale clinical trial of a long-acting injectable drug for HIV prevention. The study showed that long-acting cabotegravir (CAB LA) lowered HIV incidence among cisgender men and transgender women who have sex with men.